medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2012, Número 4

<< Anterior Siguiente >>

Acta Med 2012; 10 (4)


Melanoma. Fundamentos del diagnóstico y la terapéutica

Gallegos HJF

Idioma: Español
Referencias bibliográficas: 42
Paginas: 207-213
Archivo PDF: 343.61 Kb.


RESUMEN

El melanoma es la tercera neoplasia más frecuente en la piel, aunque la que mayor impacto en mortalidad tiene. Su etiología es multifactorial y se ha reportado que la prevalencia ha aumentado desde hace aproximadamente dos décadas. En México ocupa el séptimo lugar en frecuencia entre todas las neoplasias, 80% de los casos se encuentran en etapas localmente avanzadas. El pronóstico depende de la etapa; los factores que mayor impacto tienen en la supervivencia son el estado ganglionar, el espesor tumoral, así como la presencia de ulceración, y en los melanomas delgados a intermedios, el índice mitósico. El abordaje diagnóstico es de gran importancia para lograr una adecuada terapéutica. El apego a las normas mundiales de tratamiento nos permite obtener las mejores tasas de control locorregional, primer objetivo a lograr en pacientes con melanoma cutáneo. La finalidad del presente manuscrito es ofrecer una síntesis de los aspectos más importantes en el diagnóstico y tratamiento del melanoma cutáneo, con base en la evidencia actual obtenida en la literatura.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Selftor EA, Selftor RE et al. Reprograming metastatic melanoma cells to assume a neural cresta cell-like phenotype in an embruonic microenviroment. Proc Natl Acad Sci USA 2006; 103: 3752-3757.

  2. Puig S, Puig-Butille JA, Badenas C, Cuellar F, Malvehy. Novedades genéticas en melanoma. Piel 2006; 21: 272-274.

  3. De la Fuente García A, Ocampo Candiani J. Melanoma cutáneo. Gac Med Mex 2010; 146: 126-135.

  4. Gallegos-Hernández JF. Melanoma cutáneo. La importancia de la foto-protección y del diagnóstico oportuno. Cir Cir 2008; 76: 363-366.

  5. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003; 349: 2233-2240.

  6. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatol Surg 2006; 32: 481-492.

  7. Fernández-Flores A. Prognostic factors for melanoma progresión and metastasis: from hematoxylin-eosin to genetics. Rom J Morphol Embryol 2012; 53: 449-459.

  8. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.

  9. Balch CM, Gershenwald JE, Soong SJ. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.

  10. Edge SB, Carducci M, Byrd DR, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag, LLC; 2009.

  11. Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45: 579-586.

  12. Francken AB, Shaw HM, Thompson JF. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004; 11: 426-433.

  13. Azzola MF, Shaw HM, Thompson JF. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-1498.

  14. Griffith KA, Johnson TM. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007; 109: 100-108.

  15. Paek SC, Griffith KA, Johnson TM. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007; 109: 100-108.

  16. Gimotty PA, Elder DE, Fraker DL. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007; 25: 1129-1134.

  17. Cascinelli N, Belli F, Santinami M. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience. Ann Surg Oncol 2000; 7: 469-474.

  18. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A et al. Sentinel lymph node biopsy for melanoma; American Society of Clinical Oncology and Society of Clinical Oncology and Society of Surgical Oncology Joint clinical practice guideline. J Clin Oncol 2012; 30: 2912-2918.

  19. Garbe C, Eigentler TK, Bauer J, Blödorn-Schlicht N, Fend F, Hantschke M et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations of general practice. J Dtsch Dermatol Ges 2011; 9: 690-699.

  20. Buzaid AC, Sandler AB, Mani S. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11: 638-643.

  21. Pandalai PK, Dominguez FJ, Michaelson J, Tanabe KK. Clinical value of radiographic staging in patients diagnosed with AJCC stage III melanoma. Ann Surg Oncol 2011; 18: 506-513.

  22. Buzaid AC, Tinoco L, Ross MI. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995; 13: 2104-2108.

  23. Clark PB, Soo V, Kraas J et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006; 141: 284-288.

  24. Maubec E, Lumbroso J, Masson F et al. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res 2007; 17: 147-154.

  25. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 438-441.

  26. Balch CM, Urist MM, Karakousis CP. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-267.

  27. Cohn-Cedermark G, Rutqvist LE, Andersson R. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with coetaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89: 1495-1501.

  28. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97: 1941-1946.

  29. Thomas JM, Newton-Bishop J, A’Hern R et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-766.

  30. 30. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003; 46: 419-426.

  31. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label studyin 32 patients. Arch Dermatol 2008; 144: 943-945.

  32. Gallegos-Hernández JF, Martínez-Gómez H y Flores-Díaz R. La disección radical de cuello en cáncer de vías aerodigestivas superiores. Indicaciones, extensión y radicalidad. Cir Cir 2002; 70: 369-376.

  33. Pasquiali S, Spillane AJ, de Wilt JH, McCaffery K, Rossi CR, Quinn MJ et al. Surgeons’ opinions on lymhadenectomy in melanoma patients with positive sentinel nodes: A worldwide web-based suvey. Ann Surg Oncol 2012; 19: 4322-4329.

  34. Chakera AH, Hesse B, Burak Z, Ballinger JR, Britten A, Caracó C et al. EANM-EORTC general recomendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging 2009; 36: 1713-1742.

  35. Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozillo N et al. The impacto n morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the multicenter selective lymphadenectomy trial (I). Ann Surg Oncol 2010; 17: 3324-3329.

  36. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G, ESMO working Group. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: 86-91.

  37. Ulrich J, van Akkoi AJ, Eggermont AM, Voit C. New developments in melanoma: utility of ultrasound (inicial staging, follow-up and pre-SLNB). Expert Rev Anticancer Ther 2011; 11: 1693-701.

  38. Pilko G, Besic N, Zgajnar J, Hocevar M. Melanoma patients with ultrasonically negative regional lymph node basins have a lower tumour burden in regional lymph nodes. In: ESSOmeeting. Bordeaux: [s.e.]; 2010. Available in: http://www.essoweb.org/data/esso2010/poster/Read_Abstract.php?Id=262

  39. Gallegos-Hernández JF. Melanoma; estadificación. Cáncer&Piel 2012; 9: 3-12

  40. Agrawal S, Kane JM, 3rd, Guadagnolo BA. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 115: 5836-5844.

  41. Robert C, Thomas L, Bondarenko I. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.

  42. Chapman PB, Hauschild A, Robert C. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.




2020     |     www.medigraphic.com